- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Jason Harris Highlights National Health Council's Recommendations on Real-World Evidence
There still needs to be more education around what real-world evidence is, explained Jason Harris, associate director of policy and programs at National Health Council.
There still needs to be more education around what real-world evidence is, explained Jason Harris, associate director of policy and programs at National Health Council.
Transcript
What recommendations did the National Health Council come out with in its white paper on real-world evidence?
Recently, it’s been a real-world evidence year, if you will. We hosted a roundtable to solicit the patient perspective. We had close to 50 people in the room, about 15 experts from your more industry perspective and then about 30 patient organizations to just figure out what their concerns were, what their thoughts were, did they know about it. What we really learned from that is that overall, the concept is something that we need more education on, but once it’s explained and understood, it’s certainly something that patient organizations want to be involved in and we want to make sure that the ship doesn’t leave without insuring that perspective.
As you work with patients on real-world evidence, are you finding areas where their perceptions were not lined up with reality?
I think it’s a really good point. Overall, when we talk about the concept of what real-world evidence is and a patient hears that, they think for the most part it makes sense that it would be done because we are thinking of this high-tech era where we can use everything. It’s that understanding of well in healthcare, we are a little bit behind in terms of how we do things and so they were surprised that it wasn’t being done and that we weren’t quite there yet once they understood the concept.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
